Cytotoxicity testing of carrier-based microcomposites for DPI application
Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based microcom...
Gespeichert in:
| Veröffentlicht in: | Pharmazie 2011-07, Vol.66 (7), p.549-550 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 550 |
|---|---|
| container_issue | 7 |
| container_start_page | 549 |
| container_title | Pharmazie |
| container_volume | 66 |
| creator | Ambrus, R Pomázi, A Réti-Nagy, K Fenyvesi, F Vecsernyés, M Szabó-Révész, P |
| description | Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based
microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution,
the appropriate amount of meloxicam for dry powder inhalation could be determined. |
| doi_str_mv | 10.1691/ph.2011.0378 |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_pubme</sourceid><recordid>TN_cdi_pubmed_primary_21812334</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>govi/pharmaz/2011/00000066/00000007/art00015</ingid><sourcerecordid>govi/pharmaz/2011/00000066/00000007/art00015</sourcerecordid><originalsourceid>FETCH-LOGICAL-i343t-f4e43914231695d7a9140680dbfb3796165bf4bcc06fb3102b223089687464153</originalsourceid><addsrcrecordid>eNp1kbtPwzAQhz2AKK-NGWVjSjk_6rgjanlUQioDzJbjOK1REgfbqSh_Pe6DES93sn769N0dQjcYxphP8X2_HhPAeAy0ECfoHIDivMCMjdBFCJ8AhBMuztCIYIEJpewcLWbb6KL7ttrGbRZNiLZbZa7OtPLeGp-XKpgqa632Tru2d8GmUFY7n83fFpnq-8ZqFa3rrtBprZpgro_1En08Pb7PXvLX5fNi9vCaW8pozGtmGJ1iRmgynlSFSj1wAVVZl7SYcswnZc1KrYGnDwykJISCmHJRMM7whF6iuwO39-5rSMKytUGbplGdcUOQQmAQgjGakrfH5FC2ppK9t63yW_k3fQrMD4E0s-mikp9u8F2Slyu3sbJfK9-qH7lbqYT94_zYQCGVj6nujZb_YKw-kHaH2N1BbjjvigQkyRFTiQGErEythibKqLxc_ciQiL_kSYiv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881088443</pqid></control><display><type>article</type><title>Cytotoxicity testing of carrier-based microcomposites for DPI application</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ambrus, R ; Pomázi, A ; Réti-Nagy, K ; Fenyvesi, F ; Vecsernyés, M ; Szabó-Révész, P</creator><creatorcontrib>Ambrus, R ; Pomázi, A ; Réti-Nagy, K ; Fenyvesi, F ; Vecsernyés, M ; Szabó-Révész, P</creatorcontrib><description>Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based
microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution,
the appropriate amount of meloxicam for dry powder inhalation could be determined.</description><identifier>ISSN: 0031-7144</identifier><identifier>DOI: 10.1691/ph.2011.0378</identifier><identifier>PMID: 21812334</identifier><language>eng</language><publisher>Germany: Govi-Verlag</publisher><subject>Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - toxicity ; Cell Line, Tumor ; Cell Survival - drug effects ; Chemistry, Pharmaceutical ; Drug Carriers ; Drug Delivery Systems ; Dry Powder Inhalers ; Humans ; Polysorbates ; Povidone ; Suspensions ; Thiazines - administration & dosage ; Thiazines - toxicity ; Thiazoles - administration & dosage ; Thiazoles - toxicity</subject><ispartof>Pharmazie, 2011-07, Vol.66 (7), p.549-550</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>288,314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21812334$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ambrus, R</creatorcontrib><creatorcontrib>Pomázi, A</creatorcontrib><creatorcontrib>Réti-Nagy, K</creatorcontrib><creatorcontrib>Fenyvesi, F</creatorcontrib><creatorcontrib>Vecsernyés, M</creatorcontrib><creatorcontrib>Szabó-Révész, P</creatorcontrib><title>Cytotoxicity testing of carrier-based microcomposites for DPI application</title><title>Pharmazie</title><addtitle>Pharmazie</addtitle><addtitle>Pharmazie</addtitle><description>Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based
microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution,
the appropriate amount of meloxicam for dry powder inhalation could be determined.</description><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Chemistry, Pharmaceutical</subject><subject>Drug Carriers</subject><subject>Drug Delivery Systems</subject><subject>Dry Powder Inhalers</subject><subject>Humans</subject><subject>Polysorbates</subject><subject>Povidone</subject><subject>Suspensions</subject><subject>Thiazines - administration & dosage</subject><subject>Thiazines - toxicity</subject><subject>Thiazoles - administration & dosage</subject><subject>Thiazoles - toxicity</subject><issn>0031-7144</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kbtPwzAQhz2AKK-NGWVjSjk_6rgjanlUQioDzJbjOK1REgfbqSh_Pe6DES93sn769N0dQjcYxphP8X2_HhPAeAy0ECfoHIDivMCMjdBFCJ8AhBMuztCIYIEJpewcLWbb6KL7ttrGbRZNiLZbZa7OtPLeGp-XKpgqa632Tru2d8GmUFY7n83fFpnq-8ZqFa3rrtBprZpgro_1En08Pb7PXvLX5fNi9vCaW8pozGtmGJ1iRmgynlSFSj1wAVVZl7SYcswnZc1KrYGnDwykJISCmHJRMM7whF6iuwO39-5rSMKytUGbplGdcUOQQmAQgjGakrfH5FC2ppK9t63yW_k3fQrMD4E0s-mikp9u8F2Slyu3sbJfK9-qH7lbqYT94_zYQCGVj6nujZb_YKw-kHaH2N1BbjjvigQkyRFTiQGErEythibKqLxc_ciQiL_kSYiv</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Ambrus, R</creator><creator>Pomázi, A</creator><creator>Réti-Nagy, K</creator><creator>Fenyvesi, F</creator><creator>Vecsernyés, M</creator><creator>Szabó-Révész, P</creator><general>Govi-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20110701</creationdate><title>Cytotoxicity testing of carrier-based microcomposites for DPI application</title><author>Ambrus, R ; Pomázi, A ; Réti-Nagy, K ; Fenyvesi, F ; Vecsernyés, M ; Szabó-Révész, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i343t-f4e43914231695d7a9140680dbfb3796165bf4bcc06fb3102b223089687464153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Chemistry, Pharmaceutical</topic><topic>Drug Carriers</topic><topic>Drug Delivery Systems</topic><topic>Dry Powder Inhalers</topic><topic>Humans</topic><topic>Polysorbates</topic><topic>Povidone</topic><topic>Suspensions</topic><topic>Thiazines - administration & dosage</topic><topic>Thiazines - toxicity</topic><topic>Thiazoles - administration & dosage</topic><topic>Thiazoles - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ambrus, R</creatorcontrib><creatorcontrib>Pomázi, A</creatorcontrib><creatorcontrib>Réti-Nagy, K</creatorcontrib><creatorcontrib>Fenyvesi, F</creatorcontrib><creatorcontrib>Vecsernyés, M</creatorcontrib><creatorcontrib>Szabó-Révész, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmazie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ambrus, R</au><au>Pomázi, A</au><au>Réti-Nagy, K</au><au>Fenyvesi, F</au><au>Vecsernyés, M</au><au>Szabó-Révész, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytotoxicity testing of carrier-based microcomposites for DPI application</atitle><jtitle>Pharmazie</jtitle><stitle>Pharmazie</stitle><addtitle>Pharmazie</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>66</volume><issue>7</issue><spage>549</spage><epage>550</epage><pages>549-550</pages><issn>0031-7144</issn><abstract>Inhalation is an attractive delivery route for systemic and local therapy. High local drug concentrations may permit non-invasive delivery, lower therapeutic doses, reduced systemic side-effects, and reduced metabolic degradation of the drug in the liver. In our earlier study, carrier-based
microcomposites were prepared and investigated. The present study introduces studies of the cytotoxicity of meloxicam-containing microcomposites on monolayers of Calu-3 cells, in order to acquire information on its availability in pulmonary formulations. By relating cytotoxicity and drug dissolution,
the appropriate amount of meloxicam for dry powder inhalation could be determined.</abstract><cop>Germany</cop><pub>Govi-Verlag</pub><pmid>21812334</pmid><doi>10.1691/ph.2011.0378</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-7144 |
| ispartof | Pharmazie, 2011-07, Vol.66 (7), p.549-550 |
| issn | 0031-7144 |
| language | eng |
| recordid | cdi_pubmed_primary_21812334 |
| source | MEDLINE; IngentaConnect Free/Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antineoplastic Agents - administration & dosage Antineoplastic Agents - toxicity Cell Line, Tumor Cell Survival - drug effects Chemistry, Pharmaceutical Drug Carriers Drug Delivery Systems Dry Powder Inhalers Humans Polysorbates Povidone Suspensions Thiazines - administration & dosage Thiazines - toxicity Thiazoles - administration & dosage Thiazoles - toxicity |
| title | Cytotoxicity testing of carrier-based microcomposites for DPI application |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T18%3A20%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytotoxicity%20testing%20of%20carrier-based%20microcomposites%20for%20DPI%20application&rft.jtitle=Pharmazie&rft.au=Ambrus,%20R&rft.date=2011-07-01&rft.volume=66&rft.issue=7&rft.spage=549&rft.epage=550&rft.pages=549-550&rft.issn=0031-7144&rft_id=info:doi/10.1691/ph.2011.0378&rft_dat=%3Cpubtec_pubme%3Egovi/pharmaz/2011/00000066/00000007/art00015%3C/pubtec_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=881088443&rft_id=info:pmid/21812334&rft_ingid=govi/pharmaz/2011/00000066/00000007/art00015&rfr_iscdi=true |